<DOC>
	<DOC>NCT00882947</DOC>
	<brief_summary>The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.</brief_summary>
	<brief_title>Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Both male and female age 1865 years old The treating physician has chosen Ventavis as a suitable longterm treatment for the patient Patient with Primary Pulmonary Hypertension (i.e. IPAH or FPAH) and classified as NYHA functional class III Written informed/data protection consent No prior treatment with Ventavis or other active treatments for PPH within 6 weeks of date of study. Known or newly identified contraindication for administration of Ventavis as stated in the Ventavis product package insert.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Primary Pulmonary Hypertension (PPH)</keyword>
</DOC>